Literature DB >> 18677484

The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.

Federico Innocenti1, Snezana Mirkov, Ramamoorthy Nagasubramanian, Jacqueline Ramírez, Wanqing Liu, Wasim K Bleibel, Sunita J Shukla, Kathleen Hennessy, Gary L Rosner, Edwin Cook, M Eileen Dolan, Mark J Ratain.   

Abstract

PURPOSE: Werner's syndrome (WS) is a recessive disorder of premature onset of processes associated with aging. Defective DNA repair has been reported after exposure of cells isolated from WS patients to DNA-damaging agents. The germline 4330T>C (Cys1367Arg) variant in the WS gene (WRN) has been associated with protection from age-related diseases, suggesting it has a functional role. We studied whether the 4330T>C variant confers altered drug sensitivity in vitro.
METHODS: 4330T>C was genotyped in 372 human lymphoblastoid cell lines (LCLs) from unrelated healthy Caucasian individuals using a TaqMan-based method. The study was powered to detect the effect of the 4330T>C genotypes after exposure to camptothecin (based upon preliminary data). The effect of the 4330T>C variant on the cytotoxicity of etoposide, carboplatin, cisplatin and daunorubicin was also tested. WRN expression in 57 LCLs was measured by microarray.
RESULTS: No significant difference between the IC50 of the cells was observed among genotypes (P = 0.46) after exposure to camptothecin. No association was also observed for etoposide, carboplatin, cisplatin, and daunorubicin (ANOVA, P > 0.05). WRN expression also did not vary across genotypes (ANOVA, P = 0.37).
CONCLUSION: These results suggest that this nonsynonymous variant has relatively normal function at the cellular level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677484      PMCID: PMC2731557          DOI: 10.1007/s00280-008-0793-8

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  32 in total

1.  Werner syndrome protein 1367 variants and disposition towards coronary artery disease in Caucasian patients.

Authors:  Vilhelm A Bohr; E Jeffery Metter; Jeanine A Harrigan; Cayetano von Kobbe; Ji Lan Liu; Matthew D Gray; Alokes Majumdar; David M Wilson; Michael M Seidman
Journal:  Mech Ageing Dev       Date:  2004-07       Impact factor: 5.432

2.  Differential effects of cytotoxic drugs on mortal and immortalized B-lymphoblastoid cell lines from normal and Werner's syndrome patients.

Authors:  M Okada; M Goto; Y Furuichi; M Sugimoto
Journal:  Biol Pharm Bull       Date:  1998-03       Impact factor: 2.233

3.  Impaired nuclear localization of defective DNA helicases in Werner's syndrome.

Authors:  T Matsumoto; A Shimamoto; M Goto; Y Furuichi
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

4.  Werner and Bloom helicases are involved in DNA repair in a complementary fashion.

Authors:  Osamu Imamura; Kumiko Fujita; Chie Itoh; Shunichi Takeda; Yasuhiro Furuichi; Takehisa Matsumoto
Journal:  Oncogene       Date:  2002-01-31       Impact factor: 9.867

5.  Positional cloning of the Werner's syndrome gene.

Authors:  C E Yu; J Oshima; Y H Fu; E M Wijsman; F Hisama; R Alisch; S Matthews; J Nakura; T Miki; S Ouais; G M Martin; J Mulligan; G D Schellenberg
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

6.  An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants.

Authors:  C E Ogburn; J Oshima; M Poot; R Chen; K E Hunt; K A Gollahon; P S Rabinovitch; G M Martin
Journal:  Hum Genet       Date:  1997-12       Impact factor: 4.132

7.  Association of a polymorphic variant of the Werner helicase gene with myocardial infarction in a Japanese population.

Authors:  L Ye; T Miki; J Nakura; J Oshima; K Kamino; H Rakugi; H Ikegami; J Higaki; S D Edland; G M Martin; T Ogihara
Journal:  Am J Med Genet       Date:  1997-02-11

8.  Complex SNP-based haplotypes in three human helicases: implications for cancer association studies.

Authors:  Dimitra Trikka; Zhe Fang; Alex Renwick; Sally H Jones; Ranajit Chakraborty; Marek Kimmel; David L Nelson
Journal:  Genome Res       Date:  2002-04       Impact factor: 9.043

9.  Polymorphisms at the Werner locus: I. Newly identified polymorphisms, ethnic variability of 1367Cys/Arg, and its stability in a population of Finnish centenarians.

Authors:  E Castro; C E Ogburn; K E Hunt; R Tilvis; J Louhija; R Penttinen; R Erkkola; A Panduro; R Riestra; C Piussan; S S Deeb; L Wang; S D Edland; G M Martin; J Oshima
Journal:  Am J Med Genet       Date:  1999-02-19

Review 10.  Camptothecin sensitivity in Werner syndrome fibroblasts as assessed by the COMET technique.

Authors:  J Lowe; A Sheerin; K Jennert-Burston; D Burton; E L Ostler; J Bird; M H L Green; R G A Faragher
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

View more
  3 in total

Review 1.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

2.  Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.

Authors:  Kang Sun; Aixia Gong; Pin Liang
Journal:  Tumour Biol       Date:  2014-10-30

3.  Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.

Authors:  Nour Abdo; Menghang Xia; Chad C Brown; Oksana Kosyk; Ruili Huang; Srilatha Sakamuru; Yi-Hui Zhou; John R Jack; Paul Gallins; Kai Xia; Yun Li; Weihsueh A Chiu; Alison A Motsinger-Reif; Christopher P Austin; Raymond R Tice; Ivan Rusyn; Fred A Wright
Journal:  Environ Health Perspect       Date:  2015-01-13       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.